Prognostic Study of Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease Based on Metabolomics, and Lipidomics (BIPass II)

Qilu Hospital of Shandong University5,822 enrolled

Overview

To investigate whether there were differences in metabolomics and lipidomics in patients with coronary artery disease who had major adverse cardiovascular events during follow-up compared with those who did not.

Study Type

OBSERVATIONAL

Enrollment

5,822

Conditions

Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Hospitalized patients with the diagnosis of any type of coronary artery disease; 2. Age ≥18 years of age; 3. Patient or guardian provided informed written consent. Exclusion Criteria: 1. Prior surgery, trauma or clinically evident coagulopathic bleeding within the previous 2 weeks; 2. Bipass population with missing follow-up records in Qilu Hospital emergency follow-up cohort.

Locations (1)

Yuguo Chen

Jinan, Shandong, China

Outcomes

Primary Outcomes

major adverse cardiovascular events

cardiac death, myocardial infarction, heart failure, stroke

Time frame: 20191101-20220701

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.